Sionna Therapeutics said its cystic fibrosis strategy hit a wall in a Phase 2 trial, reporting that SION-719 did not provide additive benefit when combined with Vertex’s Trikafta. The company now plans to stop advancing the add-on program and to preserve capital while evaluating next steps. Sionna’s trial tested whether the regimen would lower sweat chloride levels more than Trikafta alone. Company messaging had framed a 10 mmol/L improvement as clinically meaningful, but the reported effect was far smaller and not statistically significant, underscoring the gap between pretrial assumptions and clinical readouts. The result has immediate portfolio and investor implications for Sionna, which had been positioned as a potential future challenger to Trikafta’s franchise. It also reinforces how difficult it can be to improve on highly effective CFTR modulator backbones in early-to-mid stage add-on designs.